Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide

Okamura, Takuma; Ichikawa, Tatsuki; Miyaaki, Hisamitsu; Miuma, Satoshi; Motoyoshi, Yasuhide; Yamashima, Mio; Yamamichi, Shinobu; Koike, Makiko; Nakano, Yusuke; Honda, Tetsurou; Yajima, Hiroyuki; Miyazaki, Osamu; Kuribayashi, Yasutaka; Ikeda, Tomonari; Taura, Naota; Nakao, Kazuwa

doi:10.3892/br.2021.1489

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that tenofovir alafenamide for hepatitis B virus (HBV) leads to the recovery titer of the bone metabolic marker, TRACP-5b (23). In that study, we speculated that HOD appears in non-cirrhotic HBV-infected patients, and that osteoblasts were normalized by HBV treatment.…”

Section: Introductionmentioning

confidence: 98%

Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C

et al. 2022

Self Cite

View full text Add to dashboard Cite

Hepatic osteodystrophy (HOD) is a common complication of chronic liver disease, including viral hepatitis. Hepatitis C virus (HCV) infection is associated with an increased risk of osteoporosis and bone mineral density (BMD) loss. Direct-acting antiviral (DAA) treatment is used to treat HCV infections; however, its effects on bone metabolism have not been reported. We compared the clinical data and bone metabolic markers at the start of DAA treatment and 1 year later in 78 patients. There were 41 female and 37 male patients. HCV was successfully treated with DAA in all patients. Bone metabolic markers included undercarboxylated osteocalcin (ucOC), 25(OH) vitamin D (VD), total type I procollagen N-propeptide (P1NP), tartrate-resistant acid phosphatase 5b (TRACP-5b), and BMD. BMD was measured in the lumbar spine (mean, L2-L4) and femoral neck using dual-energy X-ray absorptiometry. ucOC in males decreased at 1 year after treatment initiation but not in females. In males, ucOC changes were related to alterations in proteins induced by vitamin K absence-II (PIVKA-II), hemoglobin A1c, and TRACP-5b, which contributed to P1NP and lumbar BMD at the start of DAA. Changes in ucOC among women contributed to the changes in grip strength and TRACP-5b levels. DAA treatment improved ucOC, a useful bone metabolic marker, in HCV-infected male patients. Changes in ucOC contributed to changes in PIVKA-II that likely ameliorated the vitamin K deficiency. DAA treatment has been reported to improve various extrahepatic disorders and abnormal bone metabolism, especially in HOD.

show abstract

Section: Introductionmentioning

confidence: 98%

Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

The Association Between Chronic Liver Disease and Osteoporosis in East Asian Populations: A Bidirectional Mendelian Randomization Study

Wang,

Qu,

Jiang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Chronic liver disease is a widespread health problem globally, particularly common in East Asia. Osteoporosis (OP), as a common metabolic bone disease, has also gained increasing attention in aging societies. In recent years, studies have suggested a possible association between chronic liver disease and OP, but their causal relationship has not been fully or systematically studied. Objective To investigate the causal association between chronic liver disease and OP in East Asian populations using Mendelian randomization (MR) methods. Methods The datasets for chronic hepatitis B infection (CHB), chronic hepatitis C infection (CHC), and cirrhosis were sourced from the UK Biobank, while those for hepatocellular carcinoma (HCC) and OP were from the Japan Biobank. All participants included were from East Asian populations. We first treated chronic liver disease as the exposure and OP as the outcome for MR analysis, and then performed a reverse analysis treating OP as the exposure and chronic liver disease as the outcome. The inverse variance-weighted (IVW) method was used as the primary method to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs). MR-Egger and the weighted median method were used as supplementary approaches to assess the causal association between chronic liver disease and OP. Heterogeneity and pleiotropy tests were also performed to ensure the reliability of the results. Results The IVW method results indicated that CHB (ebi-a-GCST90018584) will increase the incidence of OP (bbj-a-137) (OR = 1.063, 95% CI: 1.015–1.112, p = 0.009), with no evidence of heterogeneity or pleiotropy. However, no causal association was found between CHC, cirrhosis, or HCC on OP. Reverse MR analyses did not reveal any significant causal effect of OP on chronic liver disease. Conclusion In East Asian populations, CHB will increase the incidence of OP. Therefore, CHB patients not only require long-term antiviral treatment to protect the liver but should also monitor their bone health over time to reduce the risk of OP, ultimately improving quality of life.

show abstract

Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide

Cited by 2 publications

References 29 publications

Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C

Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C

The Association Between Chronic Liver Disease and Osteoporosis in East Asian Populations: A Bidirectional Mendelian Randomization Study

Contact Info

Product

Resources

About